<DOC>
	<DOCNO>NCT00633074</DOCNO>
	<brief_summary>The purpose study show non-inferiority different formulation GlaxoSmithKline Biologicials ' influenza vaccine .</brief_summary>
	<brief_title>Non-inferiority Study GSK Biologicals ' Influenza Vaccine GSK576389A Using Different Formulations</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol enrol study . A male female 65 year age old time vaccination . Written inform consent obtain subject . Free acute aggravation health status establish clinical evaluation ( medical history medical history direct examination ) enter study . Suspected ( base clinical symptom ) confirm ( base laboratory result ) influenza infection within last 6 month . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Administration license vaccine within 2 week ( inactivated vaccine ) 4 week ( live vaccine ) prior enrolment study . Planned administration vaccine foreseen study protocol 21 day vaccination . Planned administration influenza vaccine study vaccine entire study period . Previous vaccination influenza seasonal vaccine since July 2007 . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . History hypersensitivity previous dose influenza vaccine . History allergy reaction likely exacerbate component vaccine ( ) include egg chicken protein . Acute ( active ) clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine clinical evaluation ( medical history medical history direct physical examination ) preexist laboratory screening test . Acute disease time enrolment . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period . Any medical condition IM injection contraindicate</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Influenza</keyword>
</DOC>